home / stock / antx / antx quote
$ Last:
-1.27% Change Percent:
$57.76 Open:
$56.86 Previous Close:
$58.14 High:
$56.86 Low:
315,708 Volume:
12/31/1969 07:00:00 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Stock Date | Open Price | Close Price | High | Low | Volume |
---|---|---|---|---|---|
2018-04-30 | 57.76 | 56.86 | 58.14 | 56.86 | 315,708 |
2018-04-27 | 56.92 | 57.59 | 57.86 | 56.92 | 4,322,357 |
2018-04-26 | 58.27 | 57.22 | 59.10 | 57.00 | 4,430,352 |
2018-04-25 | 55.00 | 57.61 | 57.71 | 53.8601 | 1,725,049 |
2018-04-24 | 54.85 | 54.31 | 54.99 | 53.95 | 3,790,173 |
2018-04-23 | 54.50 | 54.5654 | 55.069 | 54.43 | 303,300 |
2018-04-20 | 55.00 | 54.51 | 55.31 | 54.33 | 18,693 |
2018-04-19 | 55.54 | 54.9354 | 55.67 | 54.7454 | 10,772 |
2018-04-18 | 55.40 | 55.65 | 55.77 | 55.3298 | 554,234 |
2018-04-17 | 54.64 | 55.36 | 55.8199 | 54.64 | 3,705,905 |
2018-04-16 | 53.78 | 54.34 | 54.58 | 53.77 | 496,156 |
2018-04-13 | 53.61 | 53.50 | 53.86 | 53.46 | 370,962 |
2018-04-12 | 53.60 | 53.19 | 53.78 | 53.12 | 2,404,746 |
2018-04-11 | 54.10 | 53.75 | 54.10 | 53.74 | 4,488 |
2018-04-10 | 54.83 | 54.82 | 54.91 | 54.70 | 17,504 |
2018-04-09 | 55.37 | 54.37 | 55.37 | 54.31 | 121,751 |
2018-04-06 | 55.81 | 54.92 | 56.09 | 54.41 | 64,619 |
2018-04-05 | 55.96 | 56.36 | 56.44 | 55.6795 | 127,237 |
2018-04-04 | 55.30 | 55.85 | 55.85 | 54.85 | 22,219 |
AN2 Therapeutics Inc. Company Name:
ANTX Stock Symbol:
NYSE Market:
News, Short Squeeze, Breakout and More Instantly...
Enrolling U.S. Patients in the EBO-301 Pivotal Phase 2/3 Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Topline Results from Phase 2 Part of Trial Expected in Mid-2023 Completed Enrollment in Phase 1 PK/Safety Study of Epetraborole in Healthy Volun...
AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM lung disease, with an initial focus on treatment-refractory MAC lung disease Phase 2/3 pivotal trial expected to support regulatory approv...
On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering Continued Progress Advancing Epetraborole Clinical Program with Enrollment for Pivotal Phase 2/3 Trial in Treatment-Refractory MAC Lung Disease Expected to Beg...